Introduction Patients with atrial fibrillation experience an irregular heart rate and have an
increased risk of stroke; prophylactic treatment with anticoagulation medication reduces this …

Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

Background The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the
ARISTOTLE trial, apixaban as compared with warfarin reduced the rate of stroke, death and …

Background A previous FDA study reported a favorable benefit risk for apixaban compared
with warfarin for stroke prevention in older non-valvular atrial fibrillation (NVAF) patients (≥ …

Background Compared to aspirin, apixaban reduces stroke risk in patients unsuitable for
warfarin therapy by 63% without significantly increasing the risk of major bleeding …

Background AVERROES, a randomized controlled trial in high-risk patients with atrial
fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of …

Background Non-vitamin K oral anticoagulants (NOAC) are commonly prescribed to prevent
stroke for patients with atrial fibrillation (AF). We sought to assess factors which might …

Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …

Importance In the Apixaban for Reduction of Stroke and Other Thromboembolic
Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 …